Q2 26 EPS GAAP
$-0.18
MISS 9.09%
Est. $-0.17
Q2 26 Revenue
$4.1M
MISS 48.39%
Est. $7.8M
vs S&P Since Q2 26
+8.1%
BEATING MARKET
ABCL +8.5% vs S&P +0.4%
Market Reaction
Did ABCL Beat Earnings? Q2 2026 Results
AbCellera Biologics delivered a sharply disappointing second quarter for fiscal 2026, missing on both the top and bottom lines as a near-collapse in licensing and royalty revenue overshadowed a string of meaningful new partnerships. Total revenue cam… Read more AbCellera Biologics delivered a sharply disappointing second quarter for fiscal 2026, missing on both the top and bottom lines as a near-collapse in licensing and royalty revenue overshadowed a string of meaningful new partnerships. Total revenue came in at just $4.05 million, falling 76.3% from $17.08 million a year ago and landing well short of the $7.85 million consensus estimate, a 48.39% miss driven largely by licensing and royalty revenue crashing to $149,000 from $10.45 million in Q2 2025. The GAAP net loss widened to $55.43 million, or $0.18 per share, versus a loss of $34.73 million, or $0.12 per share, a year earlier, with the per-share result missing the $0.17 consensus by 9.09% as R&D spending climbed to $45.99 million. Against that backdrop, AbCellera secured over $112 million in combined upfront payments through new TCE platform collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals, though the stock still slipped after the Vertex announcement. Investors will look to an expected Phase 2 readout for ABCL635 in August as the next pivotal catalyst.
Key Takeaways
- • Revenue decline driven by lower research fees and significantly reduced licensing and royalty revenue
- • R&D expenses increased due to pipeline investment in internal clinical programs
- • SG&A expenses decreased year-over-year
- • New Jazz and Vertex TCE platform collaborations adding over $112 million in upfront cash
ABCL Forward Guidance & Outlook
AbCellera expects ABCL635 Phase 2 top-line data readout in Q3 2026 (August), ABCL575 Phase 1 top-line data readout in Q4 2026, and continued IND-enabling activities for ABCL386 and ABCL688. The company also aims to nominate at least one additional development candidate for IND-enabling activities in 2026. The Jazz collaboration's third program is expected to initiate within 12 months. Total available liquidity exceeds $675 million to fund the company's strategy.
ABCL YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
ABCL Revenue by Segment
With YoY comparisons, source: SEC Filings
“Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon.”
— Carl Hansen, Q2 2026 Earnings Press Release
ABCL Earnings Trends
ABCL vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABCL EPS Trend
Earnings per share: estimate vs actual
ABCL Revenue Trend
Quarterly revenue: estimate vs actual
ABCL Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 MISS | $-0.17 | $-0.18 | -9.09% | $4.1M | -48.39% |
| Q1 26 BEAT | $-0.20 | $-0.14 | +29.11% | $8.3M | +42.49% |
| Q4 25 BEAT FY | $-0.18 | $-0.03 | +83.33% | $44.9M | +569.55% |
| FY Full Year | — | $-0.49 | — | $75.1M | — |
| Q3 25 MISS | $-0.16 | $-0.19 | -17.28% | $9.0M | +41.40% |
| Q2 25 BEAT | $-0.16 | $-0.12 | +25.00% | $17.1M | +173.69% |